The present disclosure concerns a method of fabricating a curved 2D membrane comprising providing a curved polymer template on a support, flowing a solution of 2D material through the curved polymer template in order to form 2D multilayers on the curved polymer template and separating the 2D multilayers from the curved polymer template in order to form the curved 2D membrane. The curved 2D membrane is 10 characterised by a hyperbolic paraboloid curvature. The curved 2D membrane is characterised by a multi-layered lamellar morphology.
EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (USA)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Zhao, Dan
Kang, Chengjun
Wang, Yuxiang
Zhang, Zhaoqiang
Baugh, Lisa S.
Corcoran Jr., Edward W.
Calabro, David C.
Abstract
Compositions are provided corresponding to covalent organic framework materials that are doped with selected metal ions. The selected metal ions can correspond to metal ions that can both a) form a bonding complex with functional groups in the COF material, and b) after forming the bonding complex with the functional group, can further form a modified sorption complex with the imine group and a sorbed component, such as a CO2. As a result, the metal ion-doped organic framework materials can have unexpected sorption properties for sorption of components such as CO2. The metal ions can be selected in part based on "hard soft acid base" theory. Methods of sorption of components from gas phase flows are also provided.
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
3.
A SIMPLE METAL-ORGANIC FRAMEWORK FOR THE SELECTIVE ADSORPTION OF CARBON DIOXIDE FROM FLUE GAS
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
Inventor
Mullangi, Dinesh
Deng, Zeyu
Wang, Yuxiang
Wang, John
Canepa, Pieremanuele
Zhao, Dan
Cheetham, Anthony Kevin
Wei, Fengxia
Abstract
Discloses herein is an activated metal-organic framework of formula I as defined in the application, and the metal organic framework has a BET surface area of from 250 to 1,000 m2/g as obtained from a 298 K CO2 sorption isotherm. In a particular embodiment, the activated metal-organic framework is aluminium formate (AI(HCOO)3) or vanadium formate (V(HCOO)3).
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
Disclosed herein is a method of making an amino acid construct for the treatment and/or prevention of sarbecovirus infections, comprising: a. comparing amino acid sequences from at least two different sarbecovirus spike proteins or fragments thereof; b. identifying identical amino acids in the sequences from the at least two different sarbecovirus spike proteins or fragments thereof; c. removing any different amino acids from the sequences of the at least two different sarbecovirus spike proteins or fragments thereof to identify a unique amino acid sequence; and d. forming the amino acid construct of the unique amino acid sequence wherein the amino acid construct has at least 90% sequence identity to the at least two different sarbecovirus spike proteins or fragments thereof. Also disclosed are amino acid sequences generated using the method of the invention.
The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-CoV-2 antibodies.
The present invention relates to a composite membrane comprising at least one 2D material such as graphene oxide, graphene nanoplatelets or a mixture thereof, and an inorganic porous material such as gypsum, silicates and alumina. The composite membrane described herein may be housed within a separation device which may be used for selective permeation of one or more gaseous compounds.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
Disclosed herein is a nanomaterial electrolyte formed from a modified two-dimsnional nanomaterial having a surface, where the surface is modified by a plurality of functional groups selected from one or more of the group consisting of imine, sulfonic acid, sulphonamide, amine, hydroxyl, carboxylic acid, thiol, and amide on the surface of the modified two-dimensional nanomaterial, where the nanomaterial electrolyte is capable of reversibly adopting a flat two- dimensional conformation or a scrolled 1-dimensional conformation upon a change to its ambient environment. There is also disclosed a method of effecting a change in conformation from one form to the other (and back again). In a particular embodiment, the two-dimensional nanomaterial is graphene oxide or graphene and the change in the ambient environment is a change of pH.
The present invention relates to a composition comprising or consisting of two or more bacteria strains, formulated for the prophylaxis or treatment of intestinal barrier dysfunction and/or heat stress in a subject. More particularly, the composition comprises two or more of Lactobacillus reuteri MM2-3, Lactobacillus plantarum WCSF1, Streptococcus thermophilus B of R and Escherichia coli Nissle 1917. The present invention also includes uses of the invention to treat conditions such as inflammatory bowel disease (IBD) and heat stress.
The present disclosure relates to the diagnosis, treatment and prophylaxis of age-related diseases, and increasing healthspan. Provided are methods of treating or preventing an age-related disease/condition, and in particular of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject. Also provided are agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in such a method. Further provided is the use of agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in such a method.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to a method for producing a bacterial microcompartment virus-like particle (VLP) carrying a cargo molecule, the method comprising introducing and expressing in a host cell or organism one or more polynucleotides comprising (a) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding a cargo molecule fused to an encapsulation peptide comprising the sequence SKITGSSGNDTQGSLITYSGGARG, and forming a microcompartment that encapsulates the cargo molecule, or (b) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding at least one of said protomers fused with a cargo molecule or a biochemical tag, and forming a microcompartment that expresses the cargo molecule or biochemical tag on an exterior surface. In one embodiment, the bacterial microcompartment protomers are CsoSIA and CsoS4A from Halothiobacillus neapolitanus, or HO-H, HO-P and HO-T1 from Haliangium ochraceum.
Disclosed herein include recombinant terminal deoxynucleotidyl transferases (TdTs). In some embodiments, the recombinant TdT comprises an amino acid sequence that is at least 80% identical to a bovine TdT, wherein the recombinant TdT comprises one or more amino acid substitution mutations at one or more positions functionally equivalent to Glu191, Lys193, Glu194, Asp242, Lys287, Phe296, Met299, Thr342, and His421 in the bovine TdT.
The present invention relates to a method and system for identifying and validating pairs of candidate antigens and their cognate antigen-specific T lymphocytes that are useful for validating the immunogenic activity of paired antigen and TCR sequences. The method includes, inter alia, steps of determining one or more splice variants that are more highly transcribed in a sample obtained from cohort of patients compared to a reference sample, determining one or more amino acid sequences that occur in an amino acid translation of said one or more splice variants but not in the corresponding splice variant in the reference sample, and predicting HLA binding of the amino acid sequences in order to identify candidate shared antigen. The present invention also relates to methods of characterising and/or treating a medical condition, including cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The invention relates to a polymeric composite comprising poly(ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), waterborne polyurethane (WPU) and a sugar alcohol, wherein the sugar alcohol is selected from the group consisting of glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, or a combination thereof, and wherein the sugar alcohol is 20 wt% to 50 wt% of the polymer composite; an electrical device comprising such composite. The present invention also relates to methods of fabricating and its uses thereof. In particular, the present invention relates to intrinsically conductive polymer composites suitable for use in efficient dry/wet epidermal biopotential monitoring. The polymer composites are advantageously self-adhesive and stretchable, and can be used as dry electrodes.
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers
A method for producing a cannabinoid precursor by contacting a substrate and geranyl pyrophosphate or farnesyl pyrophosphate with an NphB orthologue. The NphB orthologue is from an organism other than Cannabis sativa, and the substrate can be 2,4-dihydroxy-6-pentylbenzoic acid or 2,4-dihydroxy-6-propylbenzoic acid. Also disclosed is a recombinant cell of Yarrowia lipolytica, carrying in its genome a nucleic acid encoding an NphB orthologue from an organism other than Cannabis sativa such that the NphB orthologue is expressed in the recombinant cell.
A recombinant cell of Saccharomyces cerevisiae that includes in its genome nucleic acids encoding cannabinoid biosynthetic pathway genes. A cannabinoid is produced by the recombinant cell in the presence of a cannabinoid precursor substrate and at least one of the cannabinoid biosynthetic pathway genes is from an organism other than Cannabis sativa, wherein the at least one of the cannabinoid biosynthetic pathway genes encodes a prenyltransferase. In an embodiment, the prenyltransferase is NphB from Streptomyces sp. having the amino acid sequence of any one of SEQ ID NOs: 8-11. Also disclosed is a method for producing a cannabinoid with the recombinant cell and the cannabinoid precursor substrate.
A method for producing a cannabinoid by contacting cannabigerolic acid with a cannabinoid synthase orthologue. The cannabinoid synthase orthologue is from an organism other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris that includes in its genome a nucleic acid encoding the above cannabinoid synthase orthologue. The cannabinoid synthase orthologue is expressed in the recombinant cell in an active form.
Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
18.
FUNCTIONAL BINDERS SYNTHESIZED AND SECRETED BY IMMUNE CELLS
The invention relates to an in vivo functional ligands (IFLs) including a single-chain variable fragment (scFv) domain, a fragment crystalIizable (Fc) domain, and a hinge domain joining the scFv and Fc domains. The IFLs specifically bind target receptors and are capable of triggering antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), as well as cytokine stimulation. The IFLs may be joined to a chimeric antigen receptor via a self-cleaving peptide. The IFLs may be expressed in immune cells, such as a natural killer cell or a T lymphocyte. Vectors, host cells, and methods of making IFLs are also described.
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Stewart, Colin Lawson
Singaraja, Roshni
Burke, Brian
Lee, Yin Loon
Tan, Yann Chong
Abstract
Methods for the treatment and prevention of laminopathies and diseases characterised by hyperlipidemia through LING complex inhibition are disclosed. In particular, LING complex disruption by expression of dominant-negative LING complex proteins alleviates pathophysiology in Lmna mutation-associated muscular dystrophy, progeria, and dilated cardiomyopathy. In addition, LING complex disruption by expression of dominant-negative LING complex proteins also alleviates pathophysiology in mouse models of atherosclerosis and familial hypercholesterolemia.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The invention concerns a novel cardiac therapeutic effective against atrial fibrillation (AF); a pharmaceutical composition comprising same; the use of same to treat cardiac disease; and a method of treating cardiac disease involving the use of same.
C07D 307/80 - Radicals substituted by oxygen atoms
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61P 9/00 - Drugs for disorders of the cardiovascular system
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
23.
NOVEL POLYSACCHARIDE-BASED HYDROGEL SCAFFOLDS FOR WOUND CARE
The present invention relates to a hydrogel comprising polysaccharide polymer network and collagen, particularly for use in the wound treatment. The present invention also relates to a wound dressing and a cell culture system comprising the hydrogel and their use in the wound treatment.
The present invention relates to methods of metabolic engineering bacteria cells to produce bile salt hydrolase to inhibit the germination of C. difficile endospores and colonisation within the human gastrointestinal tract. The bile salt hydrolase is operably linked to a sialic acid-inducible promoter, pNanA, of which pNanA is in turn controlled by the repressor nanR. The recombinant bacteria expressing the bile salt hydrolase can be a probiotic strain to be used for prophylaxis or treatment of C. difficile infection.
Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
Inventor
Scolnick, Jonathan
Yingting, Wang
Hoon, Shawn
Abstract
The present invention provides methods for enriching a target complementary DNA (cDNA), comprising: (a) providing a plurality of cDNAs, each comprising a first universal sequence at an end, and wherein the plurality of cDNAs comprises the target cDNA; (b) amplifying the target cDNA with a universal forward primer complementary to the first universal sequence and a gene specific reverse primer, and wherein a second universal sequence is added to an end of the cDNA opposite the first universal sequence, by a nucleic acid amplification reaction, by ligation, or by a primer extension reaction; and (c) amplifying the amplicons or extension products using the universal forward primer and a universal reverse primer complementary to the second universal sequence. In one embodiment, the universal forward primer, the gene specific reverse primer and the second universal reverse primer are provided in the same reaction mixture such that the amplifying is a single step.
A method for diagnosing Non-Small Cell Lung Cancer (NSCLC) from a sample extracted from a subject by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies against XAGE1D, LRRFIP2 and GAGE2C. Also claimed are a method of manufacturing a kit, and compositions comprising a panel of said antigens or exosomal autoantibodies.
NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD (Singapore)
NANYANG TECHNOLOGICAL UNIVERSITY (Singapore)
Inventor
Jacobsen, Jacob Pade Ramsoe
Fam, Johnson
Venkatraman, Subramanian
Abstract
Disclosed herein are a range of gastroretentive sustained release dosage forms that may be particularly useful in the delivery of 5-HTP and other agents that would benefit from delivery to the upper gastrointestinal tract.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides engineered immune cells comprising an anti-CD2 protein expression blocker (PEBL) and an anti-CD2 chimeric antigen receptor (CAR). In some embodiments, such engineered immune cells lack surface expression CD2. Also, provided herein are methods of using such cells in cancer therapies.
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
33.
NEUTRALIZATION OF HUMAN CYTOKINES WITH MEMBRANE-BOUND ANTI-CYTOKINE NON-SIGNALING BINDERS EXPRESSED IN IMMUNE CELLS
Transgenic T cells and vectors for making transgenic T cells are described. The vectors can include a nucleic acid encoding a membrane-bound anti-IL6 (mb-alL6) single chain variable fragment (scFv), and the transgenic T cells can express mb-alL6. The transgenic T cells are useful for suppressing proliferation of IL-6-dependent cells, reducing IL-6 concentration, or both. In one embodiment, the vector is a bicistronic construct encoding the mb-alL6 and an anti- CD19-41 ??-003? chimeric antigen receptor (CAR). In another embodiment, an anti-IL-6 scFv can be linked to a 41 BB and 003? domains to form an anti-IL-6 CAR. The transgenic T cells expressing said constructs can reduce the risk of cytokine release syndrome (CRS) in cancer patients being treated with CAR T cell or for the treatment of autoimmune diseases and inflammatory diseases in which cytokines are involved in pathogenesis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
THE BIOFACTORY PTE LTD (Singapore)
Inventor
Mangat, Kamarjit Singh
Hong, Rachel Tsui Ying
Lau, Andrew Chin Cheung
Tan, Gabriel Hong Chun
Wight, Ronald Craig
Abstract
A balloon-anchored, biopsy device includes a first elongated tube, a second elongated tube, and a flexible biopsy needle. A section of the first elongated tube near the distal tip may include a balloon for insertion into a blood vessel that when inflated, anchors the section in the blood vessel near a biopsy site. The second elongated tube includes a beveled distal exit of a second lumen, which may be positioned at the biopsy site when the first elongated tube is anchored in the blood vessel by the inflated balloon. The flexible biopsy needle is configured to exit the beveled distal exit for penetration into tissue at the biopsy site at a predefined angle between a longitudinal axis of the section of the first elongated tube and a longitudinal axis of the flexible biopsy needle, and to acquire a biopsy sample of the target organ at the biopsy site.
Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (United Kingdom)
THE ROYAL MARSDEN NHS FOUNDATION TRUST (United Kingdom)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Smyth, Elizabeth
Sadanandam, Anguraj
Nyamundanda, Gift
Cunningham, David
Tan, Boon Ooi Patrick
Abstract
The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
37.
T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCR.alpha..beta.- deficient T cells and CD3/TCR.alpha..beta.-deficient chimeric antigen receptor T cells that express such PEBLs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
38.
COMPOUNDS USEFUL IN INHIBITING HUMAN TREFOIL FACTOR 3
The present invention relates to compounds of Formula I, wherein A, R1 to R6, and x to z are defined herein, and their use in inhibiting Human trefoil factor 3.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
The present disclosure relates to methods for culturing human epidermal keratinocytes. When keratinocytes are cultured on plates coated with a laminin containing an alpha-4 chain or an alpha-5 chain, in a xeno-free, chemically defined cell culture medium, they expand efficiently in vitro. Useful cell culture kits for culturing keratinocytes are also described herein, as are methods of using such cells for treatment of burns or chronic wounds.
The invention relates to compounds of general formula (I): wherein R1,n, R2a,R2b and R3 are as defined herein. The compounds are inhibitors of Bc1-2-associated death promoter (BAD) phosphorylation and have anti-apoptotic activity and are useful in the treatment of cancer, particularly breast cancer, endometrial cancer, ovarian cancer, liver cancer, colon cancer, prostate cancer or pancreatic cancer.
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
41.
STIMULATORY CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
The present invention relates to genetically engineered cell populations derived from an immortalised/ cancerous cell that do not express MHC class I molecules but that are modified to express membrane-bound IL-15, membrane-bound 4-1 BBL ligand, and at least one other membrane bound molecule, such as an interleukin or anti-CD3 antibody. The co-culture of said cells with a population of immune cells results in the activation and expansion of at least one subpopulation of immune cells. Expanded populations of NK cells derived from the co-culture of a mixed cell culture with the stimulatory cell lines may be used in methods of treating cancer or an infectious disease. In a separate embodiment, a plurality of nucleic acids for use in preparing the engineered cell population are provided.
Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
Inventor
Scolnick, Jonathan
Yeo, Eugene
Hoon, Shawn
Abstract
The present invention provides methods, antibodies and kits for detecting and/or quantifying expression of both non- nucleic acid molecules, such as proteins, and nucleic acid molecules in a single sample or single cell. The antibody is covalently conjugated to an oligonucleotide, such as a single-stranded DNA molecule, which comprises an identification tag and a blocking group, such as a ddNTP or an inverted dTTP, which prevents extension of the oligonucleotide by a polymerase. The method comprises the steps of reverse transcribing the conjugated oligonucleotide and the target nucleic acid simultaneously, amplifying both transcription production, and detecting the amplicons thereof. The method is also useful for detecting and/or quantifying the number of cells in a sample expressing a given non -nucleic acid molecule (e.g. protein).
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
Inventor
Hayden, Michael
Pouladi, Mahmoud Abdulhossein
Abstract
The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 211/24 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by sulfur atoms to which a second hetero atom is attached
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
47.
BLOCKADE OF CD7 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES
The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
49.
METHODS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS
The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof. (No suitable Figure to accompany abstract for publication)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Disclosed herein is a T-helper cell ("TB-GM" cell) that is regulated by IL- 7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating TB-GM function for the treatment of, e.g., inflammatory disorders. Dia- gnostic and prognostic methods for specifically identifying TB-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as 61.11-64,8agymitAl/FgGiwdeilikatd,p2g-TB-GM-mediated (e.g., TNF-a-mediated) inflammatory disorders, are also provided.
Disclosed herein is a T-helper cell ("TH-GM" cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating TH-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying TH-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-TH-GM-mediated (e.g., TNF-a-mediated) inflammatory disorders, are also provided.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
In accordance with a version of the invention, graphene with a ferroelectric material is used as the transparent electrode material in an electrochromic device. The use of curved and dynamically flexing substrates enables flexible and stretchable applications for electrochromic films. Furthermore, the nonreactive and impermeable nature of graphene increases the durability of the device through increased resistance to external impurities. In addition, the incorporation of ferroelectric materials allows the device to exhibit nonvolatile usage; that is, devices can remain transparent with no external power source. Furthermore, devices may exhibit a charging effect, permitting recovery of energy stored in alignment of ferroelectric dipoles within the ferroelectric material.
The present disclosure is directed to chimeric receptors that binds the Fc portion of human immunoglobulin and delivers activation signals. The chimeric receptor of the present disclosure may comprise an extracellular ligand-binding domain of F158 FCGR3A or the high-affinity V158 FCGR3A variant, the hinge and transmembrane domains of CD8a, and the signaling domains of CD3? and 4-1BB. The chimeric receptor of the present disclosure has a high affinity for Rituximab, Trastuzumab, hu14.18K322A, and other therapeutic antibodies, making it useful for augmenting the efficacy of antibody therapy against various cancers.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
55.
COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS
The invention relates to compositions and methods for utilizing lysophosphatidylcholine scaffolds. The compositions and methods can be used for LPC-mediated delivery of fatty acids and other molecules; to screen and identify fatty acid formulations for parenteral nutrition; and for live animal organ imaging, among other uses. The invention also provides compositions and methods for utilizing mutations and polymorphisms in human Mfsd2a as markers for neurological deficits.
A method of achieving instrument independent measurements for quantitative analysis of fiber-optic Raman spectroscope system, the system comprising a laser source, a spectroscope and a fiber optic probe to transmit light from the laser source to a target and return scattered light to the spectroscope, the method comprising transmitting light from the laser source to a standard target having a known spectrum, recording a calibration spectrum of the scattered light from the standard target, comparing the known spectrum and the calibration system and generating a probe and/or probe-system transfer function, and storing the transfer function. Further provided is a method of performing real-time diagnostic Raman spectroscopy optionally in combination with the other disclosed methods.
Processes for forming expanded hexagonal layered minerals (HLMs) and derivatives thereof using electrochemical charging are disclosed. The process includes employing HLM rocks (20) as electrodes (100) immersed in an electrolytic slurry (50) that includes an organic solvent, metal ions and expanded HLM (24). The electrolysis introduces organic solvent and ions from the metal salt from the slurry into the interlayer spacings that separate the atomic interlayers of the HLM rock, thereby forming 1st-stage charged HLM that exfoliates from the HLM rock. The process includes expanding the electrochemically 1st-stage charged HLM by applying an expanding force.
C30B 30/02 - Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions using electric fields, e.g. electrolysis
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
Inventor
Alonso, Sylvie Claudette
Li, Rui
Locht, Camille
Abstract
Described herein are compositions, vaccines, and methods that include use of a mutated Bordetella strain against allergic diseases such as asthma and skin inflammation. Also described are kits. Other compositions, vaccines, and methods are also described.
Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.
The invention relates to methods for directing differentiation of stem cells comprising graphene. In additional embodiments, the invention relates to methods for repairing and improving bone tissue functions comprising accelerating differentiation in stem cell growth by exposing stem cells to graphene and transplanting the graphene with the exposed stem cells in the tissue at the site of repair.
The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
62.
INFLUENZA VACCINE, COMPOSITION, AND METHODS OF USE
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
Inventor
Alonso, Sylvie
Li, Rui
Chow, Vincent
Locht, Camille
Abstract
The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
patents
